Milagro Mottola

Dr. Milagro Mottola

Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC-CONICET), Córdoba, Argentina
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
SJShuai Jiang
Shuai Jiang
LSLucas Caire da Silva
Lucas Caire da Silva
TITsvetomir Ivanov
Tsvetomir Ivanov
Milagro MottolaMilagro Mottola
Milagro Mottola
KLKatharina Landfester
Katharina Landfester
In eukaryotic cells, enzymes are compartmentalized into specific organelles so that different reactions and processes can be performed efficiently and with a high degree of control. In this work, we show that these features can be artificially emulated in robust synthetic organelles constructed using an enzyme co‐compartmentalization strategy. We describe an in situ encapsulation approach that allows enzymes to be loaded into silica nanoreactors in well‐defined compositions. The nanoreactors can be combined into integrated systems to produce a desired reaction outcome. We used the selective enzyme co‐compartmentalization and nanoreactor integration to regulate competitive cascade reactions and to modulate the kinetics of sequential reactions involving multiple nanoreactors. Furthermore, we show that the nanoreactors can be efficiently loaded into giant polymer vesicles, resulting in multi‐compartmentalized microreactors.

1 November 2015 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
Milagro MottolaMilagro Mottola
Milagro Mottola
RVRaquel Viviana Vico
Raquel Viviana Vico
MVMartín E. Villanueva
Martín E. Villanueva
MFMaria Laura Fanani
Maria Laura Fanani

31 December 2019 in Nanoscale
Verified
Journal Article
Open access
PDF file
SJShuai Jiang
Shuai Jiang
DPDomenik Prozeller
Domenik Prozeller
JPJorge Pereira
Jorge Pereira
JSJohanna Simon
Johanna Simon
SHShen Han
Shen Han
KLKatharina Landfester
Katharina Landfester
Immunosuppression with glucocorticoids is a common treatment for autoimmune liver diseases and after liver transplant, which is however associated with severe side-effects. Targeted delivery of glucocorticoids to inflammatory cells, e.g. liver macrophages and Kupffer cells, is a promising approach for minimizing side effects. Herein, we prepare core–shell silica nanocapsules (SiO2 NCs) via a sol–gel process confined in nanodroplets for targeted delivery of dexamethasone (DXM) for liver immunosuppressive therapy. DXM with concentrations up to 100 mg mL−1 in olive oil are encapsulated while encapsulation efficiency remains over 95% after 15 days. Internalization of NCs by non-parenchymal murine liver cells significantly reduces the release of inflammatory cytokines, indicating an effective suppression of inflammatory response of liver macrophages. Fluorescent and magnetic labeling of the NCs allows for monitoring their intracellular trafficking and biodegradation. Controlled interaction with blood proteins and good colloidal stability in blood plasma are achieved via PEGylation of the NCs. Specific proteins responsible for stealth effect, such as apolipoprotein A-I, apolipoprotein A-IV, and clusterin, are present in large amounts on the PEGylated NCs. In vivo biodistribution investigations prove an efficient accumulation of NCs in the liver, underlining the suitability of the SiO2 NCs as a dexamethasone carrier for treating inflammatory liver diseases.

7 January 2016 in Langmuir
Verified
Journal Article
Closed access
YDYenisleidy de Las Mercedes Zulueta Díaz
Yenisleidy de Las Mercedes Zulueta Díaz
Milagro MottolaMilagro Mottola
Milagro Mottola
RVRaquel V. Vico
Raquel V. Vico
NWNatalia Wilke
Natalia Wilke
MFMaria Laura Fanani
Maria Laura Fanani

1 November 2013 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
Milagro MottolaMilagro Mottola
Milagro Mottola
NWNatalia Wilke
Natalia Wilke
LBLuciano Benedini
Luciano Benedini
RORafael Gustavo Oliveira
Rafael Gustavo Oliveira
MFMaria Laura Fanani
Maria Laura Fanani

17 March 2020 in Particle & Particle Systems Characterization
Verified
Journal Article
Open access
PDF file
SJShuai Jiang
Shuai Jiang
Milagro MottolaMilagro Mottola
Milagro Mottola
SHShen Han
Shen Han
RTRaweewan Thiramanas
Raweewan Thiramanas
RGRobert Graf
Robert Graf
KLKatharina Landfester
Katharina Landfester
Core–shell nanocapsules are receiving increasing interest for drug delivery applications. Silica nanocapsules have been the focus of intensive studies due to their biocompatibility, versatile silica chemistry, and tunable porosity. However, a versatile one‐step preparation of silica nanocapsules with well‐defined core–shell structure, tunable size, flexible interior loading, and tailored shell composition, permeability, and surface functionalization for site‐specific drug release and therapeutic tracking remains a challenge. Herein, an interfacially confined sol–gel process in miniemulsion for the one‐step versatile preparation of functional silica nanocapsules is developed. Uniform nanocapsules with diameters from 60 to 400 nm are obtained and a large variety of hydrophobic liquids are encapsulated in the core. When solvents with low boiling point are loaded, subsequent solvent evaporation converts the initially hydrophobic cavity into an aqueous environment. Stimuli‐responsive permeability of nanocapsules is programmed by introducing disulfide or tetrasulfide bonds in the shell. Selective and sustained release of dexamethasone in response to glutathione tripeptide for over 10 d is achieved. Fluorescence labeling of the silica shell and magnetic loading in the internal cavity enable therapeutic tracking of nanocapsules by fluorescence and electron microscopies. Thus, silica nanocapsules represent a promising theranostic nanoplatform for targeted drug delivery applications.